US6309826B1ExpiredUtility

88kDa tumorigenic growth factor and antagonists

83
Priority: May 23, 1997Filed: Dec 16, 1997Granted: Oct 30, 2001
Est. expiryMay 23, 2017(expired)· nominal 20-yr term from priority
Inventors:Ginette Serrero
C07K 14/475A61K 2039/505C12N 2799/026C07K 16/2896A61K 38/00C07K 2317/34A61P 35/00C07K 2317/73C07K 16/22
83
PatentIndex Score
33
Cited by
66
References
36
Claims

Abstract

This invention relates to products and methods for treating cancer and for diagnosing tumorigenicity and other diseases associated with alteration in GP88 expression or action. Antagonists to an 88 KDa autocrine growth and tumorigenicity stimulator are provided which inhibit its expression or biological activity. The antagonists include antisense oligonucleotides and antibodies.

Claims

exact text as granted — not AI-modified
What is claimed as new and desired to be protected by Letters Patent is:  
     
       1. A method for diagnosing tumorigenicity comprising the steps of: measuring the level of polynucleotide encoding human GP88 in tumorigenic tissue extracts or biological fluids; measuring the level of polynucleotide encoding human GP88 in corresponding normal or peripheral tissues; and diagnosing tumorigenicity by determining whether the measured level of polynucleotide encoding human GP88 in said tumorigenic tissue extracts or biological fluids is higher than the level in corresponding normal or peripheral tissues by an amount sufficient to indicate tumorigenicity. 
     
     
       2. A method according to claim  1  wherein said polynucleotide is mRNA. 
     
     
       3. The method according to claim  2  wherein said mRNA is measured by Northern blot analysis. 
     
     
       4. The method according to claim  2  wherein said mRNA is measured by an RNAse protection assay. 
     
     
       5. The method according to claim  2  wherein said mRNA is measured by a Reverse Transcriptase-Polymerase Chain Reaction. 
     
     
       6. The method according to claim  2  wherein said mRNA is measured by Northern blot analysis with a human GP88 cDNA probe. 
     
     
       7. The method according to claim  2  wherein said mRNA is measured by an RNAse protection assay with a human GP88 cDNA probe. 
     
     
       8. The method according to claim  2  wherein said mRNA is measured by a Reverse Transcriptase-Polymerase Chain Reaction with a human GP88 cDNA probe. 
     
     
       9. The method according to claim  6  wherein said cDNA probe is SEQ ID NO: 16. 
     
     
       10. The method according to claim  7  wherein said cDNA probe is SEQ ID NO: 16. 
     
     
       11. The method according to claim  8  wherein said cDNA probe is SEQ ID NO: 16. 
     
     
       12. The method according to claim  9  wherein said cDNA probe is labeled. 
     
     
       13. The method according to claim  10  wherein said cDNA probe is labeled. 
     
     
       14. The method according to claim  11  wherein said cDNA probe is labeled. 
     
     
       15. The method according to claim  9  wherein said cDNA probe comprises at least one modified nucleotide base. 
     
     
       16. The method according to claim  10  wherein said cDNA probe comprises at least one modified nucleotide base. 
     
     
       17. The method according to claim  11  wherein said cDNA probe comprises at least one modified nucleotide base. 
     
     
       18. The method according to claim  12  wherein said label is selected from the group consisting of enzymatic, radioisotopic, fluorescent, and chemical labels. 
     
     
       19. The method according to claim  13  wherein said label is selected from the group consisting of enzymatic, radioisotopic, fluorescent, and chemical labels. 
     
     
       20. The method according to claim  14  wherein said label is selected from the group consisting of enzymatic, radioisotopic, fluorescent, and chemical labels. 
     
     
       21. The method according to claim  1  wherein said tumorigenic tissue is human tissue. 
     
     
       22. The method according to claim  1  wherein said normal or peripheral tissue is human tissue. 
     
     
       23. The method according to claim  21  wherein said tumorigenic tissue is selected from the group consisting of adipose, brain, testes, kidney, and liver tissue. 
     
     
       24. The method according to claim  22  wherein said normal or peripheral tissue is selected from the group consisting of adipose, brain, testes, kidney, and liver tissue. 
     
     
       25. The method according to claim  21  wherein said tumorigenic tissue is breast tissue. 
     
     
       26. The method according to claim  21  wherein said tumorigenic tissue is ovarian tissue. 
     
     
       27. The method according to claim  22  wherein said normal or peripheral tissue is breast tissue. 
     
     
       28. The method according to claim  22  wherein said normal or peripheral tissue is ovarian tissue. 
     
     
       29. The method according to claim  1  wherein said normal or peripheral tissue is breast tissue from an individual patient. 
     
     
       30. The method according to claim  29  wherein said tumorigenic tissue is breast tissue from said patient. 
     
     
       31. The method according to claim  1  wherein said normal or peripheral tissue is ovarian tissue from an individual patient. 
     
     
       32. The method according to claim  31  wherein said tumorigenic tissue is ovarian tissue from said patient. 
     
     
       33. A method for diagnosing tumorigenicity in human breast tissue comprising the steps of: measuring the level of mRNA encoding human GP88 in human tumorigenic breast tissue with a GP88 cDNA probe; measuring the level of polynucleotide encoding human GP88 in corresponding normal breast tissue; and diagnosing tumorigenicity by determining whether the measured level of polynucleotide encoding human GP88 in said tumorigenic human breast tissue is higher than the level in corresponding normal human breast tissue by an amount sufficient to indicate tumorigenicity. 
     
     
       34. The method according to claim  33  wherein said cDNA probe is SEQ ID NO: 16. 
     
     
       35. A method for diagnosing tumorigenicity in human ovarian tissue comprising the steps of: measuring the level of mRNA encoding human GP88 in human tumorigenic ovarian tissue with a GP88 cDNA probe; measuring the level of polynucleotide encoding human GP88 in corresponding normal ovarian tissue; and diagnosing tumorigenicity by determining whether the measured level of polynucleotide encoding human GP88 in said tumorigenic ovarian breast tissue is higher than the level in corresponding normal human ovarian tissue by an amount sufficient to indicate tumorigenicity. 
     
     
       36. The method according to claim  35  wherein said cDNA probe is SEQ ID NO 16.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.